FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:323-324 February 1, 1996 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Acute graft-versus-host disease (GVHD) and graft rejection are the principal obstacles to successful allogeneic bone marrow transplantation. Even among recipients of transplants from HLA-identical siblings, the incidence of severe acute GVHD ranges from 20 to 50 percent, depending on the type of immunosuppressive prophylaxis given after transplantation.¹ Among recipients of apparently HLA-identical marrow from unrelated donors, the incidence of acute GVHD can reach 64 percent.²

The frequent occurrence of GVHD and graft rejection after the transplantation of marrow from HLA-identical siblings underscores the importance of factors other than HLA antigens. Two articles in this issue of the Journal address possible . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kim, S. S (2007). Treatment Options in Steroid-Refractory Acute Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation. The Annals of Pharmacotherapy 41: 1436-1444 [Abstract] [Full Text]  
• Brickner, A. G., Warren, E. H., Caldwell, J. A., Akatsuka, Y., Golovina, T. N., Zarling, A. L., Shabanowitz, J., Eisenlohr, L. C., Hunt, D. F., Engelhard, V. H., Riddell, S. R. (2001). The Immunogenicity of a New Human Minor Histocompatibility Antigen Results from Differential Antigen Processing. JEM 193: 195-206 [Abstract] [Full Text]